Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number:…

P/0201/2023 : EMA decision of 13 June 2023 on the granting of a product specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP10-23)

Reference Number: EMA/241874/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release